Compare FOSL & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FOSL | INDP |
|---|---|---|
| Founded | 1984 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 418.7M | 438.4M |
| IPO Year | 1994 | 2021 |
| Metric | FOSL | INDP |
|---|---|---|
| Price | $7.16 | $2.43 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $9.25 | N/A |
| AVG Volume (30 Days) | ★ 733.7K | 657.6K |
| Earning Date | 11-12-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.26 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,004,406,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.39 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.70 | $0.92 |
| 52 Week High | $7.33 | $5.96 |
| Indicator | FOSL | INDP |
|---|---|---|
| Relative Strength Index (RSI) | 69.18 | 48.43 |
| Support Level | $3.74 | $2.30 |
| Resistance Level | $7.33 | $2.96 |
| Average True Range (ATR) | 0.38 | 0.36 |
| MACD | 0.05 | -0.12 |
| Stochastic Oscillator | 88.98 | 18.63 |
Fossil Group Inc is a design, innovation, and distribution company in consumer fashion accessories, offering products such as watches, jewelry, handbags, small leather goods, belts, and sunglasses. It designs, develops, markets, and distributes products under its owned brands FOSSIL, SKAGEN, MICHELE, RELIC, and ZODIAC. It operates through Americas, Europe, and Asia segments, each including sales to wholesale and distributor customers, as well as Company-owned retail stores and e-commerce activities based on the location of the selling entity. The Americas segment contributes the majority of revenue and includes sales across Canada, Latin America, and the United States, while the Europe and Asia segments cover their respective regions. Each segment provides similar products and services.
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.